Welcome to our dedicated page for Zura Bio SEC filings (Ticker: ZURA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Zura Bio's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Zura Bio's regulatory disclosures and financial reporting.
Zura Bio Limited filed an amended current report to update two legal exhibits tied to a prior disclosure. Amendment No. 1 replaces in full Exhibit 5.1, the opinion of Ogier (Cayman) LLP, and Exhibit 23.1, Ogier’s consent, which were originally filed with an earlier report. The amendment states that no other portions of the original report are changed, and it lists previously filed items such as the underwriting agreement, form of pre-funded warrant, and related press releases as unchanged exhibits.
Zura Bio Limited entered into an underwriting agreement for a public offering of equity. The company is issuing 18,200,000 Class A ordinary shares at $6.25 per share and pre-funded warrants to purchase 1,800,000 ordinary shares at $6.249 per warrant.
The underwriters received a 30-day option to buy up to an additional 3,000,000 ordinary shares at the public price, and this option was exercised in full. Zura expects net proceeds of approximately $134.6 million after underwriting discounts and expenses, with closing expected on February 26, 2026, subject to customary conditions.
As of December 31, 2025, Zura estimated cash and cash equivalents of about $109.4 million. After the offering, outstanding ordinary shares are stated as 94,875,460, based on 65,018,058 shares outstanding as of September 30, 2025 and additional shares issued to Athanor Capital, assuming no exercise of the pre-funded warrants.
Zura Bio Limited is offering 18,200,000 Class A ordinary shares and pre-funded warrants to purchase 1,800,000 Class A ordinary shares. The offering is being made at a public price of $6.25 per Class A ordinary share and $6.249 per pre-funded warrant, with expected delivery on or about February 26, 2026.
The prospectus supplement states net proceeds to the company of approximately $117.0 million before expenses (or approximately $134.6 million if the underwriters fully exercise a 30-day option to purchase up to an additional 3,000,000 Class A ordinary shares). The company also discloses preliminary cash and cash equivalents of approximately $109.4 million as of December 31, 2025, subject to audit. The pre-funded warrants have a nominal exercise price of $0.001, do not expire, and include ownership limitations up to 9.99% (adjustable up to 19.99% with notice).
Zura Bio Ltd director Mark Eisner received a grant of options to acquire 37,812 shares, described as a "Share Option (Right to Buy)" at an exercise price of $0.0000 per share. These options were awarded as a grant or other acquisition.
The option vests in twelve substantially equal monthly installments over a one-year period starting on February 21, 2026. Any remaining unvested portion will vest on the day immediately preceding the next annual meeting of shareholders following the grant date, as long as he continues in service through each vesting date.
Zura Bio Ltd director Mark Eisner filed an initial Form 3 ownership report. This filing identifies him as a director of Zura Bio Ltd but does not list any stock transactions or share amounts. It serves as a baseline disclosure of his status as an insider for future reporting.
Zura Bio Limited is offering Class A ordinary shares and pre-funded warrants in a primary registered offering (preliminary prospectus supplement dated ). The pre-funded warrants have an exercise price of $0.001 and do not expire; they are exercisable subject to ownership limits (default 9.99%, adjustable to 19.99% with notice).
The company’s Class A ordinary shares trade on Nasdaq under “ZURA”; the last reported sale price on February 23, 2026 was $6.53. The prospectus discloses a preliminary cash and cash equivalents estimate of $109.4 million as of December 31, 2025 (unaudited). The share count basis used is 65,018,058 Class A ordinary shares outstanding as of September 30, 2025.
Proceeds are intended for working capital, advancing the pipeline and general corporate purposes. The offering is subject to completion of terms, underwriting arrangements, and customary conditions; information on offering size, price per share and aggregate proceeds is omitted in the provided excerpt.
Zura Bio Limited reported board changes and new director compensation terms. Neil Graham resigned from the board of directors on February 21, 2026, and the company states his resignation was not due to any disagreement with management, strategy, or operations.
On the same date, the board appointed two experienced immunology and drug development leaders, Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., as directors. Each will receive a prorated annual cash retainer of $40,000 and an initial stock option grant to purchase the lesser of 51,000 Class A ordinary shares or the number with an option value capped at $200,000, vesting over one year. They will also be eligible for similarly structured annual option grants for continued service. A press release with additional background on the new directors and Zura’s clinical-stage pipeline, including Phase 2 studies of tibulizumab (ZB-106) in hidradenitis suppurativa and systemic sclerosis, was furnished as an exhibit.
Great Point Partners, LLC and two affiliated individuals report a significant stake in Zura Bio Ltd. They beneficially own 3,815,930 Class A Ordinary Shares, representing 5.18% of the class, as of an event date of December 31, 2025.
The ownership is held through Biomedical Value Fund, L.P. with 2,632,991 shares and Biomedical Offshore Value Fund, Ltd. with 1,182,939 shares. Zura Bio had 73,680,710 shares outstanding as of December 31, 2025. The filers certify the holdings are passive and not for influencing control.
Suvretta Capital Management and related investors have filed an amended Schedule 13G reporting significant passive ownership in Zura Bio Limited. Suvretta and its principal, Aaron Cowen, each report beneficial ownership of 5,567,001 Class A ordinary shares, representing 8.6% of the class, mainly through advisory clients.
Averill Master Fund, Ltd., an advisory client of Suvretta, reports beneficial ownership of 4,995,444 shares, or 7.7% of the class. Voting and dispositive power over these shares is shared, with no sole voting or dispositive authority reported for any of the three reporting persons.
The securities are held by Suvretta’s advisory clients, and the investors certify that the shares were not acquired and are not held for the purpose of changing or influencing control of Zura Bio, but instead on a passive basis.
Zura Bio Limited furnished an updated corporate presentation dated February 11, 2026 that may be used at upcoming conferences and investor meetings. The full presentation is included as Exhibit 99.1 and can also be accessed via the News & Events section of the company’s investor website.
The company specifies that the material furnished under Item 7.01, including Exhibit 99.1, is provided under Regulation FD, is not considered “filed” for purposes of the Securities Exchange Act or Securities Act liability provisions, and is not automatically incorporated by reference into other SEC filings unless specifically referenced.